Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YSCH-01 in Recurrent Glioblastoma
NCT05914935Phase 1Unknown
- Sponsor
- Binhai Campus of the First Affiliated Hospital of Fujian Medical University
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant L-IFN adenovirus in glioblastoma (GBM), sponsored by Binhai Campus of the First Affiliated Hospital of Fujian Medical University. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 6 months. Status: unknown.
02
Drugs
recombinant L-IFN adenovirus
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05914935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914935.